Close Menu

hemophilia

Alnylam Pharmaceuticals this week provided new guidance on its key drug-development programs, noting that its flagship transthyretin-mediated amyloidosis therapy ALN-TTR02 remains poised to enter phase III testing by the end of next year, and that the development of a subcutaneou

Alnylam Pharmaceuticals this week released new preclinical data on its GalNAc conjugate delivery technology, showing that the approach could permit subcutaneous delivery of siRNAs with a wide therapeutic index.

Alnylam Pharmaceuticals this week announced new preclinical data showing that its investigational RNAi-based treatment for hemophilia, ALN-AT3, could achieve target gene knockdown after subcutaneous administration to both mice and non-human primates.

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

The study, which sequenced and characterized 20 individual genomes, is part of a larger effort at Duke that aims to sequence around 200 genomes and 500 exomes from various disease cohorts including schizophrenia, epilepsy, ALS, and HIV.

The companies will develop and use Genedata's Biologics Data Platform at Bayer Schering R&D sites in Europe and the US.

Russian and American researchers reported today that Alexei and Anastasia Romanov carried a mutation in the blood coagulation factor gene F9 that causes hemophilia B, or "Christmas disease."

Pages

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.